^
    3d
    Neoadjuvant Immunotherapy for Resectable Gastric Cancer (clinicaltrials.gov)
    P2, N=25, Completed, Qilu Hospital of Shandong University | Recruiting --> Completed | Trial completion date: Dec 2024 --> May 2024
    Trial completion • Trial completion date • Combination therapy • IO biomarker • Metastases
    |
    KDR (Kinase insert domain receptor)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin
    9d
    APPEAL: APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC (clinicaltrials.gov)
    P2, N=0, Withdrawn, Sun Yat-sen University | N=128 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK rearrangement
    |
    carboplatin • AiTan (rivoceranib) • pemetrexed
    9d
    Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis (clinicaltrials.gov)
    P2, N=30, Recruiting, Beijing 302 Hospital | Not yet recruiting --> Recruiting | Initiation date: May 2024 --> Oct 2024
    Enrollment open • Trial initiation date
    |
    AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
    15d
    Long-term survival in metastatic gastric cancer patient with Apatinib plus S-1 maintenance treatment following first-line chemotherapy-case report. (PubMed, Front Oncol)
    After Oxaliplatin combined with S-1 regimen, the effect was up to PR...The combined application of S-1 and Apatinib in gastric cancer maintenance therapy deserves further study. Maintenance therapy for gastric cancer has attracted wide attention, and more large-scale clinical research is under way.
    Journal • Metastases
    |
    KDR (Kinase insert domain receptor)
    |
    AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    16d
    Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=31, Completed, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: Feb 2024 --> Oct 2024 | Trial primary completion date: Feb 2022 --> Mar 2024 | Recruiting --> Completed
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    19d
    Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial. (PubMed, Nat Commun)
    The most common grade 3-4 treatment-related adverse events were alanine aminotransferase elevation, aspartate aminotransferase elevation, and lymphopenia. Predefined exploratory analyses indicated that patients with higher peripheral blood CXCR3 + CD8 + T cell abundance, lower immunosuppressive CD4 + T cell abundance, and higher overlap of clonotypes between tumor-infiltrating T cells and circulating T cells, were more likely to respond favorably to the combined therapy.
    P2 data • Journal • Metastases
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    22d
    Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial (clinicaltrials.gov)
    P3, N=214, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    22d
    Combination of SFRT, PD-L1 Inhibitor, and Anti-VEGF in Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Guiping People's Hospital
    New trial • Metastases
    |
    Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib)
    28d
    Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC (clinicaltrials.gov)
    P2, N=188, Recruiting, The First Affiliated Hospital of Zhengzhou University | Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: Jul 2024 --> Sep 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    30d
    First-line Treatment of Advanced/unresectable DDLPS (clinicaltrials.gov)
    P2, N=49, Not yet recruiting, Fudan University
    New P2 trial • Combination therapy • Metastases
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • pegylated liposomal doxorubicin
    1m
    MA-GC-II-019: Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Ruijin Hospital
    New P2 trial • Metastases
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    1m
    Utidelone combined with anti‑angiogenic therapy for the treatment of anthracycline/taxane‑treated and endocrine‑resistant HR+/HER2‑ refractory breast cancer with brain metastases: A case report. (PubMed, Oncol Lett)
    This result was superior to the second-line treatment with nab-paclitaxel, which resulted in a PFS of 8 months and best overall response of stable disease with slight shrinkage. The present case indicates that a combination of utidelone with apatinib/anlotinib exhibited antitumor activity in a patient with HR+/HER2- mBC with BMs. Therefore, this combination offers a promising therapeutic option for the clinical treatment of patients with breast cancer and BMs.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Focus V (anlotinib) • AiTan (rivoceranib) • albumin-bound paclitaxel • utidelone IV (UTD1)
    1m
    TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis. (PubMed, Cell Death Dis)
    The combined application of ERK inhibitors, U0126 or trametinib, with the VEGFR inhibitor Apatinib, additively suppresses angiogenesis and tumor growth of HCC1806 in nude mice. These findings provide new therapeutic strategies for TNBC.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Mekinist (trametinib) • AiTan (rivoceranib)
    1m
    Low-dose apatinib in combination with chemotherapy for hormone receptor-positive, HER2-negative breast cancer with pulmonary lymphangitic carcinomatosis: A case report. (PubMed, Medicine (Baltimore))
    This case highlights the potential antitumor activity of apatinib in breast cancer patients with presenting with PLC. While further studies are necessary, this therapeutic approach could represent a viable option for managing breast cancer in the context of a visceral crisis. The case also emphasizes the importance of individualized treatment strategies and further research to substantiate these promising findings.
    Journal • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel
    1m
    A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=16 --> 0 | Trial completion date: Nov 2028 --> Nov 2024 | Initiation date: Apr 2025 --> Nov 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Nov 2024
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date • Metastases
    |
    AiTan (rivoceranib)
    1m
    A Randomized Controlled Multicenter Clinical Study on the Safety and Efficacy of Transcatheter Arterial Chemoembolization Combined with Apatinib and Camrelizumab versus Transcatheter Arterial Chemoembolization in the Treatment of Unresectable Recurrent Hepatocellular Carcinoma (ChiCTR2400091246)
    P4, N=128, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University
    New P4 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    1m
    Efficacy and Safety of GP Chemotherapy Regimen Plus Camrelizumab Combined with Apatinib as First-Line Treatment for Nasopharyngeal Carcinoma with Liver Metastasis: A Prospective, Single-Arm, Open-Label Phase II Clinical Study (ChiCTR2400089020)
    P2, N=33, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    1m
    Drug-eluting Beads Transcatheter Arterial Chemoembolization Plus Adebrelimab and Apatinib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (TACT-01): A Single-arm, Exploratory Trial (ChiCTR2400090184)
    P2, N=31, Not yet recruiting, The First Hospital of China Medical University; The First Hospital of China Medical University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiTan (rivoceranib) • Ariely (adebrelimab)
    1m
    A Study to Evaluate SHR-1210 in Combination With Capecitabine + Oxaliplatin Sequenced by SHR-1210 + Apatinib as First-line Therapy in Treatment of Advanced Gastric Cancer (clinicaltrials.gov)
    P3, N=885, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • oxaliplatin
    1m
    Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers. (PubMed, Cancer Sci)
    The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.
    Journal • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    2ms
    Disitamab vedotin combined with apatinib in gastric cancer: A case report and review of literature. (PubMed, World J Clin Oncol)
    Despite the unfavorable prognosis associated with advanced GC, the implementation of personalized treatment approaches may still prove beneficial for select patients. In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • HER-2 amplification + PD-L1 expression • HER-2 positive + HER-2 overexpression
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • AiTan (rivoceranib) • Aidixi (disitamab vedotin) • anbenitamab (KN026)
    2ms
    E2F8-TPX2 axis regulates glycolysis and angiogenesis to promote progression and reduce chemosensitivity of liver cancer. (PubMed, Cytotechnology)
    This was mirrored by a reduction in the IC50 values for cisplatin and apatinib to 0.8257 µM and 10.79 µM, respectively. The E2F8-TPX2 axis promotes glycolysis and angiogenesis in LC cells, which in turn accelerates cancer progression and reduces chemosensitivity. The online version contains supplementary material available at 10.1007/s10616-024-00655-w.
    Journal
    |
    E2F8 (E2F Transcription Factor 8) • TPX2 (TPX2 Microtubule Nucleation Factor)
    |
    cisplatin • AiTan (rivoceranib)
    2ms
    Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review. (PubMed, Ecancermedicalscience)
    Finally, phase II clinical trials involving HER2-altered NSCLC patients demonstrated promising treatment outcomes with trastuzumab deruxtecan, trastuzumab emtansine, pyrotinib, pyrotinib + apatinib and trastuzumab + pertuzumab + docetaxel. In conclusion, the prevalence of HER2 alteration among Malaysian NSCLC patients falls within the global range. A systematic review of clinical trials revealed promising treatment outcomes and Malaysian NSCLC patients with HER2 alterations are anticipated to similarly benefit from HER2-targeted therapies.
    Retrospective data • Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 A775 • HER-2 exon 23 mutation
    |
    docetaxel • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • AiTan (rivoceranib) • Irene (pyrotinib)
    2ms
    Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children (clinicaltrials.gov)
    P2, N=44, Recruiting, Beijing Sanbo Brain Hospital | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025
    Trial completion date • Trial primary completion date
    |
    temozolomide • AiTan (rivoceranib) • etoposide oral
    2ms
    EGCG enhances antitumor effect of apatinib in nonsmall cell lung cancer by targeting VEGF signaling to inhibit glycolysis. (PubMed, Drug Dev Res)
    EGCG regulated glycolysis levels in NSCLC through VEGF overexpression, and enhanced the antitumor effect of apatinib in NSCLC through VEGF-regulated glycolysis. Taken together, EGCG strengthened the protective effects of apatinib in NSCLC through glycolysis mediated by VEGF.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • KDR (Kinase insert domain receptor) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • HK2 (Hexokinase 2) • NRP1 (Neuropilin 1) • PKM (Pyruvate Kinase M1/2)
    |
    VEGFA overexpression • VEGFA expression
    |
    AiTan (rivoceranib)
    2ms
    Apatinib has anti-tumor effects and induces autophagy in lung cancer cells with high expression of VEGFR-2. (PubMed, Iran J Basic Med Sci)
    Immunohistochemistry showed that combining apatinib with chloroquine could reduce the expression of CD31 and Ki67 and increase the expression of caspase-3. Apatinib inhibits proliferation and induces apoptosis in H1975 and H1446 lung cancer cells with high VEGFR2 expression and autophagy in H1975 and H446 cells.
    Journal • PARP Biomarker
    |
    KDR (Kinase insert domain receptor) • CASP3 (Caspase 3) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    KDR overexpression • KDR expression • CD31 expression • VEGFA expression
    |
    AiTan (rivoceranib) • chloroquine phosphate
    2ms
    Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, Beijing Tsinghua Chang Gung Hospital
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    2ms
    HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC (clinicaltrials.gov)
    P=N/A, N=97, Active, not recruiting, First Hospital of China Medical University
    New trial • Combination therapy • Checkpoint inhibition • Metastases
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • 5-fluorouracil • Tyvyt (sintilimab) • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • AiTan (rivoceranib) • Zepsun (donafenib)
    3ms
    A Phase II Study of Rivoceranib for Patients with Recurrent or Metastatic Olfactory Neuroblastoma (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Sep 2024 --> Apr 2025
    Trial initiation date
    |
    AiTan (rivoceranib)
    3ms
    BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov)
    P2, N=620, Recruiting, Fudan University | N=140 --> 620
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
    |
    Avastin (bevacizumab) • sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • SHR-A2102 • SHR-A2009 • tizetatug rezetecan (SHR-A1921)
    3ms
    A Phase II Clinical Study on Apatinib Plus Vinorelbine in Refractory HER2-Negative Breast Cancer and its Metabolic Implications of Drug Resistance. (PubMed, Curr Cancer Drug Targets)
    Apatinib combined with vinorelbine is effective and safe in patients with locally advanced or metastatic refractory HER2-negative breast cancer. The findings of this study con-tribute to a better understanding of the metabolic effect of apatinib and vinorelbine therapy.
    Clinical • P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiTan (rivoceranib) • vinorelbine tartrate
    3ms
    A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=43, Not yet recruiting, Fujian Cancer Hospital
    New P2 trial
    |
    AiTan (rivoceranib) • etoposide IV • Ariely (adebrelimab)
    3ms
    BIOVAS: BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Ruijin Hospital | Trial completion date: May 2024 --> Sep 2027 | Trial primary completion date: Feb 2024 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib)
    3ms
    mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria (clinicaltrials.gov)
    P2, N=29, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin
    3ms
    Arise-FJ-B02: Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=29, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting | N=20 --> 29 | Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Dec 2024
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + HR negative
    |
    AiTan (rivoceranib) • albumin-bound paclitaxel
    3ms
    Camrelizumab plus apatinib as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation: a single-arm, single-center, exploratory trial (ChiCTR2400088015)
    P=N/A, N=38, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University
    New trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    3ms
    Exploratory study on the combination of Adebrelimab and Apatinib in the treatment of PD-1 inhibitor induced liver cancer (ChiCTR2400087077)
    P4, N=114, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
    New P4 trial
    |
    AiTan (rivoceranib) • Ariely (adebrelimab)
    3ms
    A Single-Arm, Single-Center, Exploratory Clinical Study of Apatinib Mesylate Combined with Camrelizumab and Capox Chemotherapy as Neoadjuvant Therapy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (ChiCTR2400088196)
    P4, N=41, Not yet recruiting, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College
    New P4 trial • Metastases
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    3ms
    A Phase II Exploratory Study on the Treatment of Extensive Stage Small Cell Lung Cancer with Adbelizumab Combined with Chemotherapy and Apatinib (ChiCTR2400088229)
    P4, N=80, Not yet recruiting, Shandong University Affiliated Provincial Third Hospital; Shandong University Affiliated Provincial Third Hospital
    New P4 trial
    |
    carboplatin • AiTan (rivoceranib) • etoposide IV • irinotecan
    3ms
    An Observational Study of the Efficacy and Safety of Adebelizumab in Combination with Apatinib for Third or More Lines of Treatment in Patients with Advanced SCLC (ChiCTR2400087301)
    P2, N=30, Not yet recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital); The First Affiliated Hospital of Nanjing Medical U
    New P2 trial • Combination therapy • Metastases
    |
    AiTan (rivoceranib)
    3ms
    An exploratory clinical study of adebrelimab combined with chemotherapy and apatinib in first-line treatment of patients with extensive stage small cell lung cancer. (ChiCTR2400088296)
    P2, N=63, Not yet recruiting, China-Japan Friendship Hospital; China-Japan Friendship Hospital
    New P2 trial
    |
    cisplatin • AiTan (rivoceranib) • capecitabine • etoposide IV • Ariely (adebrelimab)
    3ms
    CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=147, Recruiting, The First Affiliated Hospital of Zhengzhou University | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date • Metastases
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Ariely (adebrelimab) • SHR-A2009